Article: Hearings to Revamp Orphan Drug Act Begin

Congress begins hearings today on legislation that would dramatically reform the Orphan Drug Act, a four-year-old bill that encourages private industry to produce drugs for rare diseases.

Rep. Henry Waxman (D-Calif.), who chairs the House Health and Environment subcommittee, has proposed eliminating the controversial provision in the existing law that gives drug companies a seven-year monopoly over any drug they develop for so-called "orphan" diseases-those with less than 200,000 patients.

Under Waxman's amendments, the Orphan Drug Act would continue to give drug manufacturers special tax incentives to develop orphan drugs. But the markets for those drugs would be thrown open for the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!